Not available
Quote | Tenax Therapeutics Inc. (NASDAQ:TENX)
Last: | $3.46 |
---|---|
Change Percent: | -2.57% |
Open: | $3.59 |
Close: | $3.46 |
High: | $3.59 |
Low: | $3.45 |
Volume: | 22,905 |
Last Trade Date Time: | 05/31/2024 03:00:00 am |
News | Tenax Therapeutics Inc. (NASDAQ:TENX)
2024-05-14 13:53:46 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips Tenax Therapeutics (NASDAQ: TENX ) just reported results for the first quarter of 2024. Tenax Therapeutics reported earnings per share of -$3.12. This was below the analys...
2024-05-14 10:42:08 ET More on Tenax Therapeutics Seeking Alpha’s Quant Rating on Tenax Therapeutics Historical earnings data for Tenax Therapeutics Financial information for Tenax Therapeutics Read the full article on Seeking Alpha For further...
Message Board Posts | Tenax Therapeutics Inc. (NASDAQ:TENX)
Subject | By | Source | When |
---|---|---|---|
Im new to this stock are they or | hawkshaw812 | investorshub | 04/05/2023 7:54:35 AM |
Where you seeing the news do you have | hawkshaw812 | investorshub | 04/03/2023 7:35:36 PM |
News is out, take a look. | I-CLICKED-IT-2 | investorshub | 04/01/2023 8:27:35 PM |
Bound to happen | hawkshaw812 | investorshub | 03/30/2023 8:38:27 PM |
Maybe when they release financials or reveal | timetomakemoney | investorshub | 03/30/2023 4:40:42 PM |
News, Short Squeeze, Breakout and More Instantly...
Tenax Therapeutics Inc. Company Name:
TENX Stock Symbol:
NASDAQ Market:
Tenax Therapeutics Inc. Website:
Currently Enrolling Patients in Phase 3 LEVEL Study with 24 Investigative Sites Initiated Secured Global Development and Commercial Rights to Levosimendan for Treatment of PH-HFpEF Expanded Intellectual Property Estate for Levosimendan with Issuance of New U.S. Patent ...
Broadens IP protection for oral (TNX-103), IV, and subcutaneous use of levosimendan, and its active metabolites (OR1896 and OR1855), in PH-HFpEF ...